| 2024 | Inhibition of the Alternative Complement Pathway May Cause Secretion of Factor B, Enabling an Early Detection of Pancreatic Cancer | JOURNAL OF PROTEOME RESEARCH |
| 2024 | Large Language Models: A Guide for Radiologists
| KOREAN JOURNAL OF RADIOLOGY |
| 2024 | Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study | JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study | GASTRIC CANCER |
| 2023 | Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
| FUTURE ONCOLOGY |
| 2023 | Prior antibiotic administration disrupts anti-PD-1 responses in advanced gastric cancer by altering the gut microbiome and systemic immune response
| CELL REPORTS MEDICINE |
| 2023 | Impact of Coronavirus Disease 2019 on Gastric Cancer Diagnosis and Stage: A Single-Institute Study in South Korea
| JOURNAL OF GASTRIC CANCER |
| 2023 | Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients
| CANCER RESEARCH AND TREATMENT |
| 2023 | ARID1A Mutation from Targeted NGS Predicts Primary Resistance to Gemcitabine and Cisplatin Chemotherapy in Advanced Biliary Tract Cancer
| CANCER RESEARCH AND TREATMENT |
| 2023 | Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers
| HEPATOLOGY |
| 2023 | Monitoring the Outcomes of Systemic Chemotherapy Including Immune Checkpoint Inhibitor for HER2-Positive Metastatic Gastric Cancer by Liquid Biopsy
| YONSEI MEDICAL JOURNAL |
| 2023 | Clinical relevance of clonal hematopoiesis and its interference in cell-free DNA profiling of patients with gastric cancer | CLINICAL CHEMISTRY AND LABORATORY MEDICINE |
| 2023 | Immunogenicity and Safety of Vaccines against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study
| CANCER RESEARCH AND TREATMENT |
| 2023 | Care Needs of Adolescents and Young Adults with Cancer Undergoing Active Treatment in South Korea: A Mixed Methods Study | JOURNAL OF ADOLESCENT AND YOUNG ADULT ONCOLOGY |
| 2023 | Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer - Authors' reply | LANCET GASTROENTEROLOGY & HEPATOLOGY |
| 2023 | Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19-14) | LANCET GASTROENTEROLOGY & HEPATOLOGY |
| 2022 | Analytical and Clinical Validation of Cell-Free Circulating Tumor DNA Assay for the Estimation of Tumor Mutational Burden | CLINICAL CHEMISTRY |
| 2022 | A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer
| NATURE COMMUNICATIONS |
| 2022 | Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer | EUROPEAN JOURNAL OF CANCER |
| 2022 | The UGT1A9*22 genotype identifies a high-risk group for irinotecan toxicity among gastric cancer patients
| Genomics & Informatics |
| 2022 | Dll4 Inhibition Promotes Graft Retention in Fat Grafting Enriched with Adipose-Derived Stem Cells
| STEM CELLS TRANSLATIONAL MEDICINE |
| 2022 | Could We Predict the Response of Immune Checkpoint Inhibitor Treatment in Hepatocellular Carcinoma?
| CANCERS |
| 2022 | Neoadjuvant FOLFIRINOX Followed by Pancreatoduodenectomy for Pancreatic Cancer in Patients with Previous Transhiatal Esophagectomy for Esophageal Cancer
| CASE REPORTS IN ONCOLOGY |
| 2022 | Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2022 | Randomized phase II study of nalicap (nalIRI/capecitabine) compared to NAPOLI ( nal-IRI/5F-U/LV) in gemcitabine-pretreated advanced pancreatic cancer: Trial-in-progress | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Phase II study of sitravatinib in combination with tislelizumab in patients with advanced biliary tract cancer who have failed to at least 1 prior systemic treatment: Trial in progress | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Phase II study of gemcitabine with oxaliplatin (GEMOX) in heavily treated patients with advanced hepatocellular carcinoma after failure of sorafenib treatment (PEACH) | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Genomic profiling as a response predictor of second-line treatment in advanced gastric cancer patients: Post-hoc analyses of two phase Ib/II trials | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | A multi-institutional, single-arm, phase II trial of neoadjuvant modified-FOLFIRINOX for resectable pancreatic ductal adenocarcinoma | JOURNAL OF CLINICAL ONCOLOGY |
| 2022 | Curative intent radical cholecystectomy followed by hyperthermic intraperitoneal chemotherapy in ruptured intraductal papillary neoplasm of gallbladder with invasive carcinoma
| Annals of Hepato-biliary-pancreatic Surgery |
| 2022 | Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma | JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES |
| 2021 | Early Diagnostic Ability of Human Complement Factor B in Pancreatic Cancer Is Partly Linked to Its Potential Tumor-Promoting Role | JOURNAL OF PROTEOME RESEARCH |
| 2021 | Deep-Learning-Based Natural Language Processing of Serial Free-Text Radiological Reports for Predicting Rectal Cancer Patient Survival
| FRONTIERS IN ONCOLOGY |
| 2021 | Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses | HEPATOLOGY |
| 2021 | Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis
| THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY |
| 2021 | Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
| CANCERS |
| 2021 | The Awareness and Usage of Big Data for Cancer in Korea: A Survey Study
| Journal of Health Informatics and Statistics(보건정보통계학회지) |
| 2021 | Prediction of Immune-Checkpoint Blockade Monotherapy Response in Patients With Melanoma Based on Easily Accessible Clinical Indicators
| FRONTIERS IN ONCOLOGY |
| 2021 | Analysis of the Molecular Signature of Breast Implant-Associated Anaplastic Large Cell Lymphoma in an Asian Patient
| AESTHETIC SURGERY JOURNAL |
| 2021 | Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
| ESMO OPEN |
| 2020 | Clinical features and KRAS mutation in colorectal cancer with bone metastasis
| SCIENTIFIC REPORTS |
| 2020 | Clinical Outcomes of Immune Checkpoint Blocker Therapy for Malignant Melanoma in Korean Patients: Potential Clinical Implications for a Combination Strategy Involving Radiotherapy
| CANCER RESEARCH AND TREATMENT |
| 2020 | Objectively measured physical activity during chemotherapy in colon cancer patients | SUPPORTIVE CARE IN CANCER |
| 2019 | Comprehensive immune profiling and immune-monitoring using body fluid of patients with metastatic gastric cancer
| Journal for Immunotherapy of Cancer |
| 2019 | S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial
| CANCER RESEARCH AND TREATMENT |
| 2018 | A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy | AAPS JOURNAL |
| 2018 | The prognostic value of volume-based parameters using<sup>18</sup>F-FDG PET/CT in gastric cancer according to HER2 status | GASTRIC CANCER |
| 2017 | PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer
| ONCOTARGET |
http://orcid.org/0000-0001-5151-5096
